Perflenapent/perflisopent

Drug Profile

Perflenapent/perflisopent

Alternative Names: EchoGen; FC 4112; QW 3600

Latest Information Update: 29 Jan 2013

Price : $50

At a glance

  • Originator Sonus Pharmaceuticals
  • Class Contrast media; Fluorocarbons; Small molecules
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 04 Apr 2008 Discontinued - Phase-I for Cardiovascular disorders (diagnosis) in Japan (Injection)
  • 20 Dec 2000 Discontinued - Registered for Cardiovascular disorders (diagnosis) in European Union (Injection)
  • 20 Oct 2000 SONUS Pharmaceuticals withdrew the NDA for EchoGen in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top